9 Meters Biopharma (NMTR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NMTR vs. SONN, OGEN, TCRT, DWTX, KZIA, SNOA, CMND, CNSP, LIXT, and CELZShould you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include Sonnet BioTherapeutics (SONN), Oragenics (OGEN), Alaunos Therapeutics (TCRT), Dogwood Therapeutics (DWTX), Kazia Therapeutics (KZIA), Sonoma Pharmaceuticals (SNOA), Clearmind Medicine (CMND), CNS Pharmaceuticals (CNSP), Lixte Biotechnology (LIXT), and Creative Medical Technology (CELZ). These companies are all part of the "pharmaceutical products" industry. 9 Meters Biopharma vs. Sonnet BioTherapeutics Oragenics Alaunos Therapeutics Dogwood Therapeutics Kazia Therapeutics Sonoma Pharmaceuticals Clearmind Medicine CNS Pharmaceuticals Lixte Biotechnology Creative Medical Technology Sonnet BioTherapeutics (NASDAQ:SONN) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Do analysts recommend SONN or NMTR? Sonnet BioTherapeutics presently has a consensus price target of $20.00, indicating a potential upside of 1,487.30%. Given Sonnet BioTherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Sonnet BioTherapeutics is more favorable than 9 Meters Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.009 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor SONN or NMTR? 9 Meters Biopharma received 15 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 84.62% of users gave Sonnet BioTherapeutics an outperform vote while only 71.15% of users gave 9 Meters Biopharma an outperform vote. CompanyUnderperformOutperformSonnet BioTherapeuticsOutperform Votes2284.62% Underperform Votes415.38%9 Meters BiopharmaOutperform Votes3771.15% Underperform Votes1528.85% Does the media refer more to SONN or NMTR? In the previous week, Sonnet BioTherapeutics had 2 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 2 mentions for Sonnet BioTherapeutics and 0 mentions for 9 Meters Biopharma. 9 Meters Biopharma's average media sentiment score of 0.00 beat Sonnet BioTherapeutics' score of -0.50 indicating that 9 Meters Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Sonnet BioTherapeutics Negative 9 Meters Biopharma Neutral Do institutionals & insiders believe in SONN or NMTR? 9.4% of Sonnet BioTherapeutics shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 2.0% of Sonnet BioTherapeutics shares are held by insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings and valuation, SONN or NMTR? Sonnet BioTherapeutics has higher revenue and earnings than 9 Meters Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonnet BioTherapeutics$1M3.86-$7.44MN/AN/A9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A Which has more risk and volatility, SONN or NMTR? Sonnet BioTherapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Is SONN or NMTR more profitable? Sonnet BioTherapeutics' return on equity of -408.93% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Sonnet BioTherapeuticsN/A -408.93% -174.13% 9 Meters Biopharma N/A -584.97%-159.45% SummarySonnet BioTherapeutics beats 9 Meters Biopharma on 8 of the 14 factors compared between the two stocks. Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTR vs. The Competition Export to ExcelMetric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$120.88M$5.31B$7.35BDividend YieldN/A3.76%5.45%4.34%P/E Ratio-0.023.0521.9417.82Price / SalesN/A4,157.44380.6697.73Price / CashN/A13.0538.2534.64Price / BookN/A34.176.453.98Net Income-$43.77M-$91.72M$3.22B$247.81M 9 Meters Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220SONNSonnet BioTherapeutics1.6212 of 5 stars$1.34+3.9%$20.00+1,392.5%-30.8%$4.11M$1M0.0010Short Interest ↑Gap DownOGENOragenicsN/A$0.19-0.8%N/A-84.5%$4.07M$40,000.00-0.035Gap UpTCRTAlaunos Therapeutics0.6747 of 5 stars$2.51-14.0%N/A-77.9%$4.02M$10,000.000.0040News CoverageGap DownDWTXDogwood TherapeuticsN/A$3.00+0.3%N/AN/A$4.00MN/A-0.465KZIAKazia Therapeutics3.3072 of 5 stars$0.79+2.5%$11.50+1,357.0%-12.2%$3.98M$2.31M0.0012Short Interest ↓Gap DownSNOASonoma Pharmaceuticals0.9762 of 5 stars$2.45+7.0%N/A+1,433.3%$3.96M$13.97M-0.61180News CoveragePositive NewsCMNDClearmind Medicine0.7029 of 5 stars$0.92-2.7%N/A-5.5%$3.94MN/A-0.49N/AGap UpCNSPCNS Pharmaceuticals1.2676 of 5 stars$1.28-4.5%$25.00+1,853.1%-99.8%$3.77MN/A-0.025Short Interest ↑LIXTLixte Biotechnology0.9399 of 5 stars$1.19-1.7%N/A-65.4%$3.75MN/A-0.694Short Interest ↓Positive NewsCELZCreative Medical Technology0.6942 of 5 stars$2.14-2.7%N/A-59.0%$3.74M$11,000.00-0.565High Trading Volume Related Companies and Tools Related Companies SONN Alternatives OGEN Alternatives TCRT Alternatives DWTX Alternatives KZIA Alternatives SNOA Alternatives CMND Alternatives CNSP Alternatives LIXT Alternatives CELZ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMTR) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NMTR Stock Free NMTR Stock Alerts